Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Epcoritamab combinations demonstrate promising efficacy in patients (pts) with Richter transformation (RT): First results from arms 2B (epcor + lenalidomide LEN) and 2C (epcor + R-CHOP) of the phase 1b/2 EPCORE CLL-1 trial

View Full Paper
Ask AI
Bookmark
Share

Authors

SSSylvia SnauwaertAZ Sint-JanMŠMartin ŠimkovičUniversity Hospital Hradec KrálovéJLJavier López‐JiménezInstituto Cajal

Discussion

Loading...

Member takes

Implication

First trial results demonstrate 82% overall response with epcor+LEN in Richter transformation, indicating potential for treatment.

Key Points

  • This research assesses the efficacy of epcoritamab combinations in treating Richter transformation in chronic lymphocytic leukemia.
  • Phase 1b/2 EPCORE CLL-1 trial evaluated epcor in combination with lenalidomide or R-CHOP.
  • Participants included biopsy-proven CD20+ DLBCL-RT patients with a history of CLL or small lymphocytic lymphoma.
  • Overall response rate (ORR) and complete response (CR) were primary endpoints measured by PET-CT.
  • In Arm 2B, ORR was 82% and CR rate was 73% after a median follow-up of 12.6 months.
  • Arm 2C showed an ORR of 73% and CR rate of 60% with a median follow-up of 10.1 months.
  • Common treatment-emergent adverse events included cytokine release syndrome, neutropenia, and anemia.

Cite This Study

Snauwaert et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d449https://doi.org/10.1182/blood-2025-1015
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Epcoritamab monotherapy demonstrates promising efficacy in patients with Richter transformation (RT): 2-year follow-up results from arm 2A of the phase 1b/2 EPCORE CLL-1 trial2025
  2. 2Epcoritamab (epcor) + chemoimmunotherapy (CIT) in patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL) eligible for autologous stem cell transplant (ASCT): Pooled results from arms 4 and 10 of EPCORE NHL-2.2026
  3. 3Fixed-duration epcoritamab monotherapy induces high response and MRD-negativity rates in elderly patients with newly diagnosed large B-cell lymphoma (LBCL) and comorbidities: Results from EPCORE DLBCL-32025 · 2 citations
  4. 4Epcoritamab with rituximab + lenalidomide (R2) and epcoritamab maintenance deliver deep and durable remissions in previously untreated (1L) follicular lymphoma (FL): 3-year outcomes from epcore NHL-2 arms 6 and 72025 · 2 citations
  5. 5primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma2025 · 2 citations